Silica-coated magnetite nanoparticles labeled by nimotuzumab, a humanised monoclonal antibody to epidermal growth factor receptor: preparations, specific targeting and bioimaging

J Nanosci Nanotechnol. 2013 Oct;13(10):6541-5. doi: 10.1166/jnn.2013.6640.

Abstract

Uniform fluorescein isothiocyanate (FITC)-incorporated silica-coated core-shell SPIO nanoparticles (MNP@SiO2) with sizes of about 30 nm have been prepared by controlled hydrolysis of tetraethyl orthosilicateb. Monoclonal antibody nimotuzumab (h-R3) is labeled to the core-shell MNP@SiO2 for targeting to cancer cell A431 overexpressing epidermal growth factor receptor (EGFR). The result shows h-R3 labeled MNP@SiO2 nanoparticle (MNP@SiO2-mAb(h_R3)) has desired specificity to cancer cell A431. Compared to BSA labeled MNP@SiO2 nanoparticle (MNP@SiO2-BSA), MNP@SiO2-mAb(h_R3) could increase the cellular uptake of endocytosis and cytotoxicity due to h-R3 binding.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Humanized / chemistry
  • Antibodies, Monoclonal, Humanized / immunology*
  • Cell Line, Tumor
  • ErbB Receptors / immunology*
  • Humans
  • Magnetite Nanoparticles*
  • Silicon Dioxide / chemistry*

Substances

  • Antibodies, Monoclonal, Humanized
  • Magnetite Nanoparticles
  • nimotuzumab
  • Silicon Dioxide
  • ErbB Receptors